#News for #Investors and #Media: We are announcing new data from the first randomised head-to-head study comparing daily oral 2-drug regimen vs 3-drug regimen in treatment-naïve adults at #AIDS2026. Through our specialist HIV company, ViiV Healthcare, our goal is to empower individuals and communities, driving towards a future where HIV is no longer a global health threat. 🔗 Find out more in the press release: https://bit.ly/4yIHYqw
About us
We are uniting science, technology and talent to get ahead of disease together. Our community guidelines: https://gsk.to/socialmedia
- Website
-
http://www.gsk.com
External link for GSK
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- London, England
- Type
- Public Company
- Specialties
- Pharmaceutical products and Vaccines
Locations
Employees at GSK
Updates
-
The landscape of HIV prevention and care has transformed dramatically over a generation and continues to evolve through scientific innovation. From early, challenging regimens to more patient-centred longer-acting options, advances in research aim to give people more choice, agency, and the freedom to live full lives. Our latest article from Behind the Science magazine explores how GSK and ViiV Healthcare are dedicated to combining deep scientific understanding with advanced technologies to redefine HIV prevention and treatment. We focus on the development of longer-lasting options which aim to simplify care, improve adherence, and ultimately enhance quality of life. We believe long-acting approaches are shaping the future, offering more than convenience – they will hopefully change how people live with HIV. 🔗 Read more about this remarkable journey and the future of HIV care: https://bit.ly/4x1YEYi #AIDS2026
-
#News for #Investors and #Media: Today we announced that the US Food and Drug Administration (FDA) granted approval for one of our therapies to treat ROS1-positive non-small cell lung cancer. Learn more: https://gsk.to/4gQO5mn
-
It’s almost time…✈️ GSK and ViiV Healthcare, our specialist HIV company, are heading to #AIDS2026 in Rio de Janeiro where we're excited to show our deep commitment to long-acting HIV innovation. Our R&D approach, uniting our deep understanding of the immune system with advanced technologies, drives our efforts to prevent and treat diseases. This helps us bring new medicines to patients faster, ensuring no person living with HIV is left behind. 🔗 Find out more about our approach to HIV: https://bit.ly/4vDD7El
-
What happens when something as automatic as breathing becomes a daily struggle? The "Behind the Science" podcast is back with a powerful new episode that dives deep into respiratory diseases affecting millions of people worldwide. Join host Dr. Kat Arney as she explores the realities of Chronic Obstructive Pulmonary Disease (COPD), a condition that can make even the simple act of breathing a struggle, impacting everything from exercise and sleep to everyday moments we often take for granted. In this episode, Kat is joined by two leading experts: Dr. Kaivan Khavandi (Senior Vice President and Global Head of Respiratory, Immunology and Inflammation Research at GSK) and Professor Dave Singh (specialist in respiratory pharmacology at the The University of Manchester). Together, they shed light on the real-world impact of this disease, the serious risks of flare-ups, and why ongoing research is crucial to improving patient lives. Available on all your favourite podcast platforms now. Give it a listen and let us know what you think! 👇 Full episode here: https://gsk.to/4wZvr0u #BTSPodcast
-
GSK leaders were in Oxford last week, reinforcing the value of our collaborative partnerships and the groundbreaking science taking place. We're proud to collaborate with leading experts across the UK life sciences sector and are optimistic about the future health impact we can achieve together.
Great to be in Oxford last week - seeing first-hand the cutting-edge research and innovation happening in our partnerships. This is a truly exciting time for GSK. Advances in science, data and technology are creating new opportunities to get medicines and vaccines to patients faster than ever before, but real progress means being bold – challenging convention and having the courage to work differently. In this case, bringing academia and industry together to speed up innovation against some of the world's toughest health challenges. That's why partnerships with institutions like Oxford matter so much. The University brings together world-class translational capabilities which, together with our R&D scale and expertise, shortens the journey from discovery to patient impact. Looking ahead, our path is clear: we’ll keep building partnerships that bring complementary strengths and get life-changing medicines to patients, faster.
-
-
#News for #Investors and #Media: We’ll be at #AIDS2026 with ViiV Healthcare, our specialist HIV company, presenting research and insights from our innovative portfolio and integrase strand transfer inhibitor (INSTI)-powered pipeline. Our mission: to leave no person living with HIV behind. Find out more in the press release 👉 https://gsk.to/4vGMTFW
-
-
#News for #Media and #Investors: Today we announced that the EMA has accepted our submission to update the label of one of our meningococcal vaccines. If approved, this could enable a 1-dose booster for certain individuals. Learn more: https://gsk.to/4b1gkuT
-
#News for #Investors and #Media: Today marks another step forward for a GSK-developed vaccine candidate, reflecting our commitment to working in partnership to help ensure scientific innovation impacts the health of people and communities who need it most. Our strategic focus on leveraging decades of scientific leadership in antigen discovery and adjuvant technology is helping advance vaccines to help tackle infectious diseases worldwide. Learn more: https://gsk.to/455XBdZ
-
#News for #investors and #media: Today we announced the completion of our acquisition of clinical-stage precision oncology company Nuvalent, Inc., bringing in multiple lung cancer assets to our existing oncology portfolio. Find out more: https://gsk.to/3T1uzts